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Objectives: To evaluate economic impact of linezolid (LZD) versus vancomycin 
(VAN) for treatment of confirmed methicillin-resistant Staphylococcus aureus(MRSA) 
nosocomial pneumonia (NP) in German health care system. MethOds: A 4 week 
decision model was developed capturing 1st and 2nd line therapy. Published lit-
erature (primarily Wunderink 2012, reported 54.8% clinical efficacy for LZD vs. 
44.9% for VAN in modified Intent-to-Treat population at End of Study for treat-
ment of MRSA NP) and expert opinion provided clinical and resource use data, 
such as efficacy, mortality, adverse events (AEs), treatment duration, and length 
of hospital/ICU stay. German cost data was obtained from published literature. 
Base-case analysis used 10-day treatment duration. In event of treatment failure/
severe AEs on 1st-line therapy, drug was switched after 7 days. Costs were reported 
in 2012 Euros. Results: LZD was associated with minimally lower costs (€ 16,119 
vs. € 16,144), and greater overall treatment success compared to VAN, resulting 
in LZD ‘dominating’ VAN. About 80% of treatment costs were related to hospital 
stay, primarily ICU (72%). Drug therapy, physician visits, laboratory tests and AEs/
treatment failure each account for ≤ 5% of total costs. Several scenarios were 
tested by varying treatment duration (7 or 14 days), and varying discontinuation/
switch of therapy (at 5 or 10 days). In cases of shorter treatment duration (7 day) or 
delayed switch of therapy (at 10 day), linezolid continues to ‘dominate’. However, 
with 14 day treatment duration or early switch (at 5 day) linezolid becomes more 
costly, but still has greater effectiveness resulting in a relatively low Incremental 
Cost Effectiveness Ratio (ICER) of € 8,207 and € 2,343 per successfully treated 
patient. cOnclusiOns: LZD is a cost-effective alternative to VAN for treatment 
of MRSA-confirmed NP, owing primarily to its higher clinical response rate. Future 
analyses should use other country costs/resource use data to test result generaliz-
ability and assess empiric treatment phase.
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Objectives: Despite available treatment options chronic hepatitis C virus (HCV) 
infection remains a significant disease burden in Denmark, in particular among 
genotype 1 difficult-to-treat patients The aim of this study was to evaluate the 
cost effectiveness of boceprevir (BOC), a protease inhibitor, in combination with 
pegylated interferon plus ribavirin (PEG+R), compared to PEG+R alone, among treat-
ment naïve and treatment experienced genotype 1 HCV patients. MethOds: A 
Markov model simulating antiviral therapy and disease progression was devel-
oped to estimate the lifetime health care costs and clinical outcomes of alternative 
treatment strategies. The model simulated the treatment regimens of dual therapy 
(PEG+R) and triple therapy (PEG+R+BOC), respectively, as recommended in the sum-
mary of product (SPC) and the Danish treatment guidelines. Data on clinical effi-
cacy was taken from phase III clinical trials (SPRINT-2 and RESPOND-2). Costs were 
measured in 2012 Danish Kroner (DKK) and clinical outcomes in quality adjusted 
life years (QALYs). The incremental cost-effectiveness ratio (ICER) was estimated 
for treatment naïve and experienced patients. Deterministic and probabilistic sen-
sitivity analyses (PSA) on clinical inputs, costs, health state utility values, and SVR 
rates were performed to assess the overall decision uncertainty. Results: The ICER 
for PEG+R+BOC therapy versus standard of care with PEG+R was DKK 241.774 for 
treatment naïve HCV patients and DKK 98.371 for treatment experienced patients. 
PSA for treatment naïve patients showed a probability of cost-effectiveness of 
PEG+R+BOC therapy compared to PEG+R of more than 65 % at a willingness-to-pay 
threshold of DKK 300.000 (approx. £30.000). cOnclusiOns: From a Danish health 
sector perspective, the model suggests PEG+R+BOC therapy is cost effective in HCV 
genotype 1 patients to prevent development of late manifestations in the liver, 
such as cirrhosis and hepatocellular carcinoma (HCC) irrespectively of treatment 
experience status.
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Objectives: To estimate, from a Spanish Healthcare System perspective, the cost-
effectiveness of the usage of telaprevir (TVR) with peginterferon and ribavirin (PR) 
in patients with mild fibrosis (METAVIR F2) vs. patients with bridging fibrosis or 
cirrhosis (METAVIR scores F3 and F4, respectively). MethOds: A decision tree model 
was developed to assess cost-efficacy of TVR+PR according to the degree of fibrosis 
and previous response to treatment in patients with HCV Genotype 1. Treatment 
costs were estimated excluding futility rules but contemplating the potential to 
shorten treatment in treatment-naïve and relapsers that are either F2 or F3. The 
efficacy of triple therapy treatment by patient type is derived from the TVR phase 
III clinical trials. To estimate cost-effectiveness, the following values were calcu-
lated for each alternative: the cost per cured patient and the number of cured and 
not cured patients assuming a fixed budget. Results: TVR+PR in F2 patients has 
a lower cost per cured patient than F3+F4 both in naïve patients (20% less) and in 
experienced patients (in relapsers: 5% less; in partial responders: 47% less; and in 
null responders: 39% less). This difference is statistically significant for naïve and 
partial responding patients. For a 1 million EUR investment in each patient type, 
resources allocated to F2 patients offers maximum cured patients (94 in F2 vs. 71 
in F3+F4) and minimum non-cured patients (37 in F2 vs. 58 in F3+F4). This conclu-
sion stands when different sensitivity analyses are conducted. cOnclusiOns: The 
usage of TVR+PR in patients with mild fibrosis could be a more cost-effective alter-
native than in patients with bridging fibrosis or cirrhosis regardless of the patient’s 
previous response to treatment. A long-term cost-effectiveness analysis is required 
in order to validate this data.
therapy. The aim of this study was to assess the cost-effectiveness (CE) of Linezolid 
against generic Vancomycin as an empiric therapy for VAP patients, from the health 
care payer’s perspective. MethOds: A decision-tree model was used to compare 
costs and effectiveness of Linezolid (600 mg/12 hours) and Vancomycin (1g / 12 
hours) (comparator) for a cohort of patients with VAP. Effectiveness measures were: 
microbiological success rates, mortality rates, ICU and ward LOS and overall costs. 
Effectiveness and epidemiologic data were collected from published literature. Local 
costs (2012 US$) were obtained from Costa Rica’s Health System official databases. 
The model used a 12-week time horizon and only direct medical costs were consid-
ered (hospital LOS, medication costs, hematologic, gastrointestinal and skin adverse 
events and lab exams). Monte Carlo probabilistic sensitivity analysis (PSA) was 
constructed. Results: Results showed Linezolid as more effective and less expen-
sive option for VAP. Clinical success rate was higher with Linezolid (64.4%) against 
Vancomicyn, (56.1%). Mortality was lower with linezolid (10.13% vs 15.74%). Average 
ICU (and ward) LOS was 18 (9) days with Linezolid and 22 (10) days with Vancomycin. 
Overall medical costs per patient were $87782.52 with Linezolid and $92771.51 with 
Vancomycin. CE analyses showed Linezolid is the dominant strategy. cOnclusiOns: 
This is the first CE study for VAP developed in Costa Rica. Linezolid resulted as the 
cost-saving option for treating VAP patients in the Costa Rican clinical environment.
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Objectives: To compare the cost-effectiveness of telaprevir associated with 
peginterferon and ribavirin (TVR+PR) compared to peginterferon and ribavirin (PR) 
alone in the treatment of patients with METAVIR scale F2) fibrosis and with previ-
ously untreated chronic hepatitis C genotype 1. MethOds: Markov model, Curtis 
et al 2012, was adapted to a Brazilian public payer perspective. The model estimated 
chronic hepatitis C disease progression based on transition probabilities for a cohort 
of patients with F2 fibrosis. Clinical outcomes and drug dosage were taken from 
the phase-3 trial (Marcellin et al), with the SVR-rate for TVR+PR as 79% and 49% for 
PR in patients with F2 fibrosis. Drug costs of TVR and PR were gathered from the 
ministry of health website, www.comprasnet.gov.br. Costs associated with each 
disease state were gathered from a study by Barros et al. A discount rate of 3.5 % and 
a lifetime horizon were assumed. Results: TVR+PR therapy resulted in higher costs 
(R$ BRL57,164 vs BRL27,971) and better outcomes (278 cirrhosis avoided per 1,000 
patients) compared to PR alone. Treatment with TVR+PR resulted in 19.94 life years 
gained compared to PR alone with 19.19. TVR+PR was estimated to give a quality 
adjusted life year (QALY) expectancy of 13.83, 1.16 higher than with PR (12.67 QALYs), 
resulted in an incremental cost-effectiveness ratio (ICER) of R$23,734 per QALY 
gained. Compared to PR alone, the treatment with TVR+PR avoided about 11 deaths 
and 17 liver transplants per 1,000 treated patients. Treatment with TVR+PR resulted 
in an incremental cost of R$1,595 per liver transplant avoided and R$2,613 per death 
avoided compared to PR alone. cOnclusiOns: Treating F2 fibrosis patients with 
TVR+PR was cost-effective compared with PR alone with an ICER below to the WHO 
recommended threshold. The benefits of TVR+PR treatment were clear with the low 
incremental cost per death or liver transplant avoided.
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Objectives: WHO recommends Post-Exposure Prophylaxis (PEP) in countries like 
France, where rabies cases observed are linked to bats or imported. This study aims 
to assess effectiveness and cost-effectiveness of anti-rabies PEP algorithms in this 
low rabies risk countries. MethOds: A model-based analysis simulated PEP admin-
istration incorporating risk of rabies according to exposure categories (CII: minor 
scratches; CIII: transdermal bite(s)), PEP strategy, and risk of death on car crash in 
trips to anti-rabies centers. Strategies compared were: A) No PEP for CII and CIII; B) 
vaccine for CIII only; C) vaccine for CII and CIII; D) vaccine+immunoglobulins for 
CIII only; E)vaccine for CII and vaccine+immunoglobulins for C III. We simulated the 
trajectory of 2,807 patients exposed to unobservable dogs in Metropolitan France, in 
2011. Model parameters were estimated from French and international literature. 
The probability that the dog to which the patient was exposed is rabid was 4x10-9 
and the average risk of death on car crash in trips to anti-rabies centers was 7x10-
7. Total vaccine, immunoglobulins and consultation costs for Zagreb regimens (4 
vaccine injections) were € 160, € 700 and € 70, respectively. Results: Strategy E led 
to the lowest number of rabies cases (4.36x10-8), the highest costs (€ 2,493,000), but 
also to 1.74x10-3 lethal car crashes. Strategy A had the highest number of rabies 
cases (5.71x10-6), but no risk of lethal crash and no costs; therefore it was the most 
effective and the least costly strategy. In the sensitivity analysis when the probability 
that the dog is rabid was> 1.4x10-6, strategy D becomes more effective than strategy 
A; and when> 1.4x10-4, strategy B becomes cost-effective (i.e. cost-effectiveness ratio 
vs. A> 3x French GPD= € 30,000). cOnclusiOns: In 2011, in France, anti-rabies PEP 
appears to be less effective and more expensive than No PEP. These model-based 
results could be used by decision makers to establish national guidelines.
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